- Did you mean
- mrsa
Search results - 63 results
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022.
last PSV dose). We measured VE overall, by vaccine category/product, age group and time since first mRNA booster dose, adjusting by site as a fixed effect, and by swab date, age, sex, and ...
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021.
SARI patients ≥ 20 years with symptom onset ≥ 150 days from last PSV dose, VE for complete Comirnaty PSV was 54% (95% CI: 18-74). Among those receiving Comirnaty PSV and mRNA booster (any product) ≥ 150 ...
Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients.
Transplantation Prospective Studies SARS-CoV-2 Transplant Recipients Vaccination Abstract: As solid organ transplant recipients are at high risk of severe COVID-19 and respond poorly to primary SARS-CoV-2 mRNA ...
Third dose of COVID-19 mRNA vaccine closes the gap in immune response between naïve nursing home residents and healthy adults.
a frail and old population group, respond poorly to primary mRNA COVID-19 vaccination. A third dose has been shown to boost protection against severe disease and death in this immunosenescent population, ...
Homologous versus heterologous prime-boost COVID-19 vaccination: impact on clinical severity of Omicron among hospitalized COVID-19 patients in Belgium
confirmed by whole genome sequencing and vaccinated with a homologous (mRNA for prime/mRNA for boost) or heterologous (viral vector for prime/mRNA for boost) prime-boost vaccination schedule were included in ...
Homologous and Heterologous Prime-Boost Vaccination: Impact on Clinical Severity of SARS-CoV-2 Omicron Infection among Hospitalized COVID-19 Patients in Belgium
investigated effectiveness of (1) mRNA booster vaccination versus primary vaccination only and (2) heterologous (viral vector-mRNA) versus homologous (mRNA-mRNA) prime-boost vaccination against severe outcomes ...
Third dose of COVID-19 mRNA vaccine closes the gap in immune response between naïve nursing home residents and healthy adults
Publication Type: Peer reviewed scientific article Authors: Pannus, Pieter; Stéphanie Depickère; Kemlin, Delphine; Georges, Daphnée; Houben, Sarah; Olislagers, Véronique; Waegemans, Alexandra; De Craeye, Stéphane; Antoine Francotte; Chaumont, Félicie; Van ...
Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial
I Desombere; Kevin K. Ariën; Maria Goossens Source: PLOS Global Public Health, Volume 2, Issue 12 (2022) Keywords: COVID-19; fractional dose; reduced dose; mRNA vaccination; non-inferiority; SARS-CoV-2 Abstract: ...
Accuracy of high-risk HPV DNA PCR, p16(INK4a) immunohistochemistry or the combination of both to diagnose HPV-driven oropharyngeal cancer
HPV mRNA; Oropharyngeal carcinoma; HPV-AHEAD Abstract: Background The incidence of high-risk human papillomavirus (hrHPV)-driven head and neck squamous cell carcinoma, in particular oropharyngeal ...
Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients.
Stéphanie Humblet-Baron Source: Front Immunol, Volume 13 (2022) Keywords: 2019-nCoV Vaccine mRNA-1273 Antibodies, Viral BNT162 Vaccine COVID-19 COVID-19 Vaccines Humans Immunocompromised Host mRNA Vaccines ...